- Conditions
- Metastatic Melanoma, Metastasis to Brain
- Interventions
- Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Standard of Care Craniotomy
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 364
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, Metastatic Triple Negative Breast Cancer
- Interventions
- CTLA-4 Antibody, Hypofractionated Radiotherapy
- Drug · Radiation
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Melanoma
- Interventions
- dacarbazine, CP-675,206, temozolomide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 55
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 45 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma
- Interventions
- Vudalimab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Houston, Texas
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
- Drug
- Lead sponsor
- Adagene Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Interventions
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- ipilimumab
- Biological
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Cryosurgery, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tremelimumab
- Procedure · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
- Biological · Other · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Ipilimumab, Nivolumab, Tocilizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Botensilimab, Balstilimab, Standard of Care
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
- Interventions
- GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 276
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 184 more
- Conditions
- Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- Balstilimab, Zalifrelimab
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Newport Beach, California + 4 more
- Conditions
- Melanoma
- Interventions
- Ipilimumab, 6MHP
- Drug · Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- CB-839, Nivolumab
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
- Interventions
- DRP-104, atezolizumab
- Drug · Biological
- Lead sponsor
- Dracen Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
- Interventions
- Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy, Ipilimumab, Laboratory Biomarker Analysis
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 10 more
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Ipilimumab, Local Consolidation Therapy, Nivolumab, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery
- Biological · Procedure · Other + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Conroe, Texas • Houston, Texas • League City, Texas + 1 more
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic
- Interventions
- Nivolumab, Ipilimumab, Nintedanib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida